Interim 2023/24 Influenza A Vaccine Effectiveness: VEBIS European Primary Care and Hospital Multicentre Studies, September 2023 to January 2024

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

Citing Articles

Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023-2024 Season.

Choi Y, Song J, Wie S, Lee J, Lee J, Jeong H Vaccines (Basel). 2025; 13(2).

PMID: 40006743 PMC: 11861641. DOI: 10.3390/vaccines13020197.

Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.

Blanquart F, Vieillefond V, Visseaux B, Abou Chakra C, Nunes M, Jacques A Euro Surveill. 2025; 30(7).

PMID: 39980426 PMC: 11843621. DOI: 10.2807/1560-7917.ES.2025.30.7.2500074.

Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season.

Sun Y, Shi W, Zhang D, Ma C, Feng Z, Zhang J Euro Surveill. 2025; 30(7).

PMID: 39980425 PMC: 11843618. DOI: 10.2807/1560-7917.ES.2025.30.7.2500084.

Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.

Rose A, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg H Euro Surveill. 2025; 30(7).

PMID: 39980423 PMC: 11843620. DOI: 10.2807/1560-7917.ES.2025.30.7.2500102.

Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design.

Gharpure R, Regan A, Nogareda F, Cheng A, Blyth C, George S Lancet Glob Health. 2025; 13(2):e203-e211.

PMID: 39890222 PMC: 11783037. DOI: 10.1016/S2214-109X(24)00473-X.

References

Maurel M, Pozo F, Perez-Gimeno G, Buda S, Seve N, Oroszi B . Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir Viruses. 2024; 18(1):e13243. PMC: 10777262. DOI: 10.1111/irv.13243. View

Smolarchuk C, Ickert C, Zelyas N, Kwong J, Buchan S . Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. Euro Surveill. 2024; 29(2). PMC: 10785209. DOI: 10.2807/1560-7917.ES.2024.29.2.2300709. View

Skowronski D, Zhan Y, Kaweski S, Sabaiduc S, Khalid A, Olsha R . 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN). Euro Surveill. 2024; 29(7). PMC: 10986657. DOI: 10.2807/1560-7917.ES.2024.29.7.2400076. View

Rose A, Pozo F, Martinez-Baz I, Mazagatos C, Bossuyt N, Cauchi J . Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir Viruses. 2024; 18(2):e13255. PMC: 10894713. DOI: 10.1111/irv.13255. View